Tofacitinib/baricitinib (DrugBank: Tofacitinib, Baricitinib)
9 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
41 | Giant cell arteritis | 0 |
46 | Malignant rheumatoid arthritis | 1 |
49 | Systemic lupus erythematosus | 0 |
50 | Dermatomyositis | 0 |
93 | Primary biliary cholangitis [Primary biliary cirrhosis (~Mar 2017)] | 0 |
107 | Juvenile idiopathic arthritis [Systemic juvenile idiopathic arthritis (~Mar 2018)] | 0 |
265 | Lipodystrophy | 0 |
268 | Nakajo-Nishimura syndrome | 0 |
325 | Hereditary autoinflammatory syndrome | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03440892 (ClinicalTrials.gov) | November 1, 2017 | 14/2/2018 | Effects of Antirheumatic Treatment on Levels of Survivin in Rheumatoid Arthritis Patients | Longitudinal Observational Study on Rheumatoid Arthritis Patients: Effects of Antirheumatic Treatment on Serum Levels of Survivin | Rheumatoid Arthritis | Drug: methotrexate;Drug: sulfasalazine;Drug: abatacept;Drug: tocilizumab;Drug: tofacitinib/baricitinib | Vastra Gotaland Region | NULL | Recruiting | 20 Years | N/A | All | 2500 | Sweden |